Vistagen Therapeutics Stock News

Equities analysts expect VistaGen Therapeutics, Inc. (NASDAQ:VTGN) to report sales of $330,000.00 for the current fiscal quarter, Zacks reports. Two analysts have made estimates for VistaGen Therapeutics earnings, with estimates ranging from $300,000.00 to $360,000.00. VistaGen Therapeutics posted sales of $310,000.00 during the same quarter last year, which suggests a positive year over year growth []

SOUTH SAN FRANCISCO, Calif., Nov. 16, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics, Inc . (NASDAQ: VTGN), a biopharmaceutical company committed to developing and commercializing a new generation of medicines with the potential to go beyond the current standard of care for anxiety, depression, and other central nervous system (CNS) disorders, today announced that Shawn Singh, Chief Executive Officer, will participate in a fireside chat with Jefferies analyst, Andrew Tsai as part of the Jefferies Virtual London Healthcare Conference on Thursday, November 18, 2021. Management will be available during the conference for virtual one-on-one meetings.

VistaGen Therapeutics, Inc. (NASDAQ:VTGN) Stock analysts at William Blair reduced their Q3 2022 earnings estimates for VistaGen Therapeutics in a research report issued on Thursday, November 11th. William Blair analyst T. Lugo now forecasts that the company will post earnings of ($0.08) per share for the quarter, down from their prior estimate of ($0.07). []

VistaGen Therapeutics' (VTGN) CEO Shawn Singh on Q2 2022 Results - Earnings Call Transcript

VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of -40.00% and 9.48%, respectively, for the quarter ended September 2021. Do the numbers hold clues to what lies ahead for t

Study Launches Phase 2A Clinical Program Designed to Explore PH94B's Potential in Multiple Additional Anxiety Disorders

PALISADE Phase 3 Program focused on PH94B's potential as a rapid-onset, acute treatment of anxiety in adults with social anxiety disorder PALISADE Phase 3 Program focused on PH94B's potential as a rap

VistaGen Therapeutics, Inc. (VTGN) delivered earnings and revenue surprises of 20.00% and -4.58%, respectively, for the quarter ended June 2021. Do the numbers hold clues to what lies ahead for the st

VistaGen Therapeutics, Inc. (VTGN) CEO Shawn Singh on Q1 2022 Results - Earnings Call Transcript

Shares of VistaGen Therapeutics (NASDAQ:VTGN) fell 1.5% in after-market trading after the company reported Q1 results. Quarterly Results Earnings per share were up 42.86% over the past year to ($0.04)

PALISADE Phase 3 Program to evaluate PH94B for rapid-onset acute treatment of anxiety in adults with social anxiety disorder (SAD) progressing on plan

SOUTH SAN FRANCISCO, Calif., Aug. 02, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potentia

SOUTH SAN FRANCISCO, Calif., July 09, 2021 (GLOBE NEWSWIRE) -- VistaGen Therapeutics (NASDAQ: VTGN), a biopharmaceutical company committed to developing a new generation of medicines with the potentia

Ms. Rotunno brings extensive healthcare industry expertise as a leader and strategist as VistaGen advances late-stage development of its product candidates for anxiety and depression disorders Ms. Rot

Making a penny stocks watchlist for 2021? Check these 8 out The post Are These 8 Penny Stocks to Watch on Your List Right Now?